| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_939f235e47e545f507e87cd08b5189d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c5423b6df1c55b5578d3efcc71a8097 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-599
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-852
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2302 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09 |
| filingDate |
2009-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fa432371d35308351a6b8a903c7f619 |
| publicationDate |
2011-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2011001315-A |
| titleOfInvention |
Pancreatic cancer immunotherapy |
| abstract |
An immunotherapeutic agent that prolongs the survival period of patients with pancreatic cancer is provided. An immunotherapeutic agent obtained by culturing autologous peripheral blood lymphocytes of a pancreatic cancer patient by stimulation with an anti-CD3 antibody and an anti-CD52 antibody, which is administered to the pancreatic cancer patient at least four times. The number of activated lymphocytes contained in a dose per administration is at least 15 × 10 9 , the proportion of CD3 - CD56 + NK cells among the activated lymphocytes is at least 30%, and a specific amount Administration is started for a pancreatic cancer patient in at least one state among a plurality of immunocompromised states. [Selection figure] None |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9339537-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016151741-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015528110-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-5016732-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015038040-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012117532-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017137784-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015073442-A |
| priorityDate |
2009-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |